CombiGene’s Chairman and CEO increase their shareholdings in the company
Chairman Arne Ferstad and CEO Jan Nilsson have increased their shareholdings in CombiGene by 300,000 and 100,000 shares, respectively. The seller is the company’s majority owner, Lars Thunberg. The sale has been made at the current market price.
“The sale of shares in CombiGene to Arne Ferstad and Jan Nilsson is an excellent way of strengthening the ties between CombiGene and the company’s two key people,” says Lars Thunberg. “That the sale was transacted at the current market price demonstrates the great confidence Arne and Jan have in the future of CombiGene.”
“Gene therapy is currently one of the pharma industry’s most promising areas and has fantastic potential to revolutionize the treatment of a wide range of serious diseases. CombiGene’s project portfolio now includes two exciting projects: one for treatment of difficult-to-treat epilepsy and one for treatment of the rare disease lipodystrophy. CombiGene is now in a very interesting phase of development and our increase in holdings in the company reflects the positive expectations we have for the future,” commented CombiGene board chairman Arne Ferstad and CEO Jan Nilsson in a joint statement.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.